美国头颈癌临床试验的多样性：我们有进步吗？
Diversity in U.S. Clinical Trials for Head and Neck Cancer: Are We Improving?
作者信息
Zuckerman Melani Camryn, Edwards Heather Ann
机构信息
Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Boston Medical Center Department of Otolaryngology, Boston, Massachusetts, USA.
出版信息
Head Neck. 2025 Feb;47(2):679-686. doi: 10.1002/hed.27943. Epub 2024 Oct 14.
BACKGROUND
This study assesses whether national initiatives undertaken to improve diversity in clinical trial enrollment have been successful within head and neck cancer (HNC) trials.
METHODS
A retrospective analysis was conducted of HNC trials published on clinicaltrials.gov with start dates between 2000 and 2023. Demographic data for 8998 HNC trial enrollees was abstracted and analyzed to investigate potential demographic shifts.
RESULTS
In the past 20 years, the percentage of White patients increased 6.1%, Asian patient population decreased 3.1%, and Black patient population increased 0.8%. Compared with previously published SEER data, HNC trials have significantly more White patients, fewer Black patients, and fewer Asian/Native-Hawaiian patients than HNC patients at large.
CONCLUSIONS
Despite efforts to increase diversity in HNC clinical trials in the United States, diversity has significantly decreased in the past 10 years. As current approaches are failing to show improvement, novel approaches to improving representation in clinical trials are necessitated.
背景
本研究评估为提高临床试验入组多样性而开展的国家举措在头颈癌（HNC）试验中是否取得成功。
方法
对在clinicaltrials.gov上发布的、开始日期在2000年至2023年之间的HNC试验进行回顾性分析。提取并分析了8998名头颈癌试验入组者的人口统计学数据，以调查潜在的人口统计学变化。
结果
在过去20年中，白人患者的比例增加了6.1%，亚洲患者群体减少了3.1%，黑人患者群体增加了0.8%。与之前公布的监测、流行病学与最终结果（SEER）数据相比，HNC试验中的白人患者明显更多，黑人患者更少，亚洲/夏威夷原住民患者也比总体HNC患者更少。
结论
尽管美国努力增加HNC临床试验的多样性，但在过去10年中，多样性显著下降。由于目前的方法未能显示出改善，因此需要采用新的方法来提高临床试验中的代表性。
Zotero 插件